Low-grade oncocytic renal tumour - Revision history

Michael: /* IHC */

2025-03-18T23:53:26Z

IHC

← Older revision		Revision as of 23:53, 18 March 2025
Line 79:		Line 79:
	*CD10 -ve.		*CD10 -ve.
	*L1CAM +ve.<ref name=pmid38460672>{{cite journal \|authors=Alghamdi M, Chen JF, Jungbluth A, Koutzaki S, Palmer MB, Al-Ahmadie HA, Fine SW, Gopalan A, Sarungbam J, Sirintrapun SJ, Tickoo SK, Reuter VE, Chen YB \|title=L1CAM Expression and Molecular Alterations Distinguish Low Grade Oncocytic Tumor (LOT) from Eosinophilic Chromophobe Renal Cell Carcinoma \|journal=Mod Pathol \|volume= \|issue= \|pages=100467 \|date=March 2024 \|pmid=38460672 \|doi=10.1016/j.modpat.2024.100467 \|url=}}</ref>		*L1CAM +ve.<ref name=pmid38460672>{{cite journal \|authors=Alghamdi M, Chen JF, Jungbluth A, Koutzaki S, Palmer MB, Al-Ahmadie HA, Fine SW, Gopalan A, Sarungbam J, Sirintrapun SJ, Tickoo SK, Reuter VE, Chen YB \|title=L1CAM Expression and Molecular Alterations Distinguish Low Grade Oncocytic Tumor (LOT) from Eosinophilic Chromophobe Renal Cell Carcinoma \|journal=Mod Pathol \|volume= \|issue= \|pages=100467 \|date=March 2024 \|pmid=38460672 \|doi=10.1016/j.modpat.2024.100467 \|url=}}</ref>

			===Comparison between some renal tumours with eosinophilic cytoplasm===
			{\| class="wikitable sortable"
			!Tumour
			![[CK7]]
			![[CD117]]
			![[GATA3]]
			\|-
			\| [[Renal oncocytoma]]
			\| -ve †
			\| +ve
			\| -ve/+ve
			\|-
			\| [[Chromophobe renal cell carcinoma]]
			\| +ve ‡
			\| +ve
			\| -ve
			\|-
			\| Low-grade oncocytic tumour
			\| +ve
			\| -ve
			\| +ve
			\|-
			\|}
			† may have scattered positive cells<br>
			‡ diffuse and strong

	==Molecular==		==Molecular==

Michael: +L1CAM

2024-03-26T12:37:07Z

+L1CAM

← Older revision		Revision as of 12:37, 26 March 2024
Line 78:		Line 78:
	*CK20 -ve.		*CK20 -ve.
	*CD10 -ve.		*CD10 -ve.
			*L1CAM +ve.<ref name=pmid38460672>{{cite journal \|authors=Alghamdi M, Chen JF, Jungbluth A, Koutzaki S, Palmer MB, Al-Ahmadie HA, Fine SW, Gopalan A, Sarungbam J, Sirintrapun SJ, Tickoo SK, Reuter VE, Chen YB \|title=L1CAM Expression and Molecular Alterations Distinguish Low Grade Oncocytic Tumor (LOT) from Eosinophilic Chromophobe Renal Cell Carcinoma \|journal=Mod Pathol \|volume= \|issue= \|pages=100467 \|date=March 2024 \|pmid=38460672 \|doi=10.1016/j.modpat.2024.100467 \|url=}}</ref>

	==Molecular==		==Molecular==

Michael at 04:08, 20 March 2024

2024-03-20T04:08:57Z

← Older revision		Revision as of 04:08, 20 March 2024
Line 102:		Line 102:

	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|2}}

	[[Category:Diagnosis]]		[[Category:Diagnosis]]
	[[Category:Genitourinary pathology]]		[[Category:Genitourinary pathology]]

Michael: touch

2024-03-20T04:08:44Z

touch

← Older revision		Revision as of 04:08, 20 March 2024
Line 19:		Line 19:
	\| Clinicalhx = often incidentally discovered mass		\| Clinicalhx = often incidentally discovered mass
	\| Signs =		\| Signs =
	\| Symptoms =		\| Symptoms =
	\| Prevalence =		\| Prevalence =
	\| Bloodwork =		\| Bloodwork =

Michael at 04:07, 20 March 2024

2024-03-20T04:07:50Z

← Older revision		Revision as of 04:07, 20 March 2024
Line 10:		Line 10:
	\| IHC = CK7 +ve, CD117 -ve, GATA3 +ve, [[PAX8]] +ve		\| IHC = CK7 +ve, CD117 -ve, GATA3 +ve, [[PAX8]] +ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular = TSC/mTOR pathway mutation
	\| IF =		\| IF =
	\| Gross =		\| Gross =
Line 80:		Line 80:

	==Molecular==		==Molecular==
	*[[Renal neoplasms with TSC/mTOR mutations\|TSC/mTOR pathway mutation]].<ref name=pmid35203531>{{cite journal \|authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O \|title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background \|journal=Biomedicines \|volume=10 \|issue=2 \|pages= \|date=January 2022 \|pmid=35203531 \|pmc=8869370 \|doi=10.3390/biomedicines10020322 \|url=}}</ref>		*[[Renal neoplasms with TSC/mTOR pathway mutations\|TSC/mTOR pathway mutation]].<ref name=pmid35203531>{{cite journal \|authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O \|title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background \|journal=Biomedicines \|volume=10 \|issue=2 \|pages= \|date=January 2022 \|pmid=35203531 \|pmc=8869370 \|doi=10.3390/biomedicines10020322 \|url=}}</ref>

	==Sign out==		==Sign out==

Michael at 04:06, 20 March 2024

2024-03-20T04:06:55Z

← Older revision		Revision as of 04:06, 20 March 2024
Line 78:		Line 78:
	*CK20 -ve.		*CK20 -ve.
	*CD10 -ve.		*CD10 -ve.

			==Molecular==
			*[[Renal neoplasms with TSC/mTOR mutations\|TSC/mTOR pathway mutation]].<ref name=pmid35203531>{{cite journal \|authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O \|title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background \|journal=Biomedicines \|volume=10 \|issue=2 \|pages= \|date=January 2022 \|pmid=35203531 \|pmc=8869370 \|doi=10.3390/biomedicines10020322 \|url=}}</ref>

	==Sign out==		==Sign out==

	<pre>		<pre>
	Right Kidney Mass, Biopsy:		Right Kidney Mass, Biopsy:

Michael at 04:05, 20 March 2024

2024-03-20T04:05:27Z

← Older revision		Revision as of 04:05, 20 March 2024
Line 29:		Line 29:
	}}		}}
	'''Low-grade oncocytic renal tumour''', abbreviated '''LOT''', is an unusual [[renal tumour]] that does not neatly fit into any WHO renal neoplasia category. It is also known as '''renal oncocytic tumour that is CD117 negative and CK7 positive'''.		'''Low-grade oncocytic renal tumour''', abbreviated '''LOT''', is an unusual [[renal tumour]] that does not neatly fit into any WHO renal neoplasia category. It is also known as '''renal oncocytic tumour that is CD117 negative and CK7 positive'''.

			''Low-grade oncocytic tumour'' directs to here.

	Whether it is a distinct entity is not clear as of 2019.<ref name=pmid30895640/> It can be considered an emerging entity that may be in the WHO classification of renal neoplasia in the future.<ref name=pmid31936678>{{cite journal \|authors=Siadat F, Trpkov K \|title=ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification \|journal=Cancers (Basel) \|volume=12 \|issue=1 \|pages= \|date=January 2020 \|pmid=31936678 \|pmc=7017067 \|doi=10.3390/cancers12010168 \|url=}}</ref>		Whether it is a distinct entity is not clear as of 2019.<ref name=pmid30895640/> It can be considered an emerging entity that may be in the WHO classification of renal neoplasia in the future.<ref name=pmid31936678>{{cite journal \|authors=Siadat F, Trpkov K \|title=ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification \|journal=Cancers (Basel) \|volume=12 \|issue=1 \|pages= \|date=January 2020 \|pmid=31936678 \|pmc=7017067 \|doi=10.3390/cancers12010168 \|url=}}</ref>

Michael at 19:14, 1 March 2024

2024-03-01T19:14:20Z

← Older revision		Revision as of 19:14, 1 March 2024
Line 66:		Line 66:
	*[[GATA3]] +ve.		*[[GATA3]] +ve.
	**GATA3 very rarely positive in RCCs (1/71 clear cell RCC, 0/53 papillary RCC, 2/33 chromophobe RCC).<ref name=pmid2431520>{{cite journal \|authors=Gonzalez-Roibon N, Faraj SF, Munari E, Bezerra SM, Albadine R, Sharma R, Argani P, Allaf ME, Netto GJ \|title=Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms \|journal=Hum Pathol \|volume=45 \|issue=2 \|pages=244–8 \|date=February 2014 \|pmid=24315206 \|doi=10.1016/j.humpath.2013.08.020 \|url=}}</ref>		**GATA3 very rarely positive in RCCs (1/71 clear cell RCC, 0/53 papillary RCC, 2/33 chromophobe RCC).<ref name=pmid2431520>{{cite journal \|authors=Gonzalez-Roibon N, Faraj SF, Munari E, Bezerra SM, Albadine R, Sharma R, Argani P, Allaf ME, Netto GJ \|title=Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms \|journal=Hum Pathol \|volume=45 \|issue=2 \|pages=244–8 \|date=February 2014 \|pmid=24315206 \|doi=10.1016/j.humpath.2013.08.020 \|url=}}</ref>
	**GATA3 occasionally positive in oncocytoma (9/47 cases).<ref name=pmid2431520/>		**GATA3 occasionally positive in [[renal oncocytoma]] (9/47 cases).<ref name=pmid2431520/>
	*PAX8 +ve.		*PAX8 +ve.
	*CD117 -ve.		*CD117 -ve.

Michael: tweak

2024-02-21T16:03:34Z

tweak

← Older revision		Revision as of 16:03, 21 February 2024
Line 8:		Line 8:
	\| LMDDx = [[renal oncocytoma]], [[chromophobe renal cell carcinoma]] eosinophilic variant, [[clear cell renal cell carcinoma]] eosinophilic variant, [[papillary renal cell carcinoma]] oncocytic variant, [[tubulocystic carcinoma of the kidney]], other [[renal tumours with eosinophilic cytoplasm]], benign [[liver]]		\| LMDDx = [[renal oncocytoma]], [[chromophobe renal cell carcinoma]] eosinophilic variant, [[clear cell renal cell carcinoma]] eosinophilic variant, [[papillary renal cell carcinoma]] oncocytic variant, [[tubulocystic carcinoma of the kidney]], other [[renal tumours with eosinophilic cytoplasm]], benign [[liver]]
	\| Stains =		\| Stains =
	\| IHC = CK7 +ve, CD117 -ve, [[PAX8]] ~~+ve, GATA3~~ +ve		\| IHC = CK7 +ve, CD117 -ve, GATA3 +ve, [[PAX8]] +ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular =
Line 65:		Line 65:
	*CK7 +ve.		*CK7 +ve.
	*[[GATA3]] +ve.		*[[GATA3]] +ve.
	**~~Very~~ rarely positive in RCCs (1/71 clear cell RCC, 0/53 papillary RCC, 2/33 chromophobe RCC).<ref name=pmid2431520>{{cite journal \|authors=Gonzalez-Roibon N, Faraj SF, Munari E, Bezerra SM, Albadine R, Sharma R, Argani P, Allaf ME, Netto GJ \|title=Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms \|journal=Hum Pathol \|volume=45 \|issue=2 \|pages=244–8 \|date=February 2014 \|pmid=24315206 \|doi=10.1016/j.humpath.2013.08.020 \|url=}}</ref>		**GATA3 very rarely positive in RCCs (1/71 clear cell RCC, 0/53 papillary RCC, 2/33 chromophobe RCC).<ref name=pmid2431520>{{cite journal \|authors=Gonzalez-Roibon N, Faraj SF, Munari E, Bezerra SM, Albadine R, Sharma R, Argani P, Allaf ME, Netto GJ \|title=Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms \|journal=Hum Pathol \|volume=45 \|issue=2 \|pages=244–8 \|date=February 2014 \|pmid=24315206 \|doi=10.1016/j.humpath.2013.08.020 \|url=}}</ref>
	**~~May be~~ positive in oncocytoma (9/47 cases).<ref name=pmid2431520/>		**GATA3 occasionally positive in oncocytoma (9/47 cases).<ref name=pmid2431520/>
	*PAX8 +ve.		*PAX8 +ve.
	*CD117 -ve.		*CD117 -ve.
Line 85:		Line 85:
	Comment:		Comment:
	The tumour stains as follows:		The tumour stains as follows:
	POSITIVE: CK7 (strong, diffuse~~), CD117 (very focal~~), PAX8 (strong, diffuse), AE1/AE3, ~~AMACR, E~~-~~cadherin~~, ~~BerEP4~~.		POSITIVE: CK7 (strong, diffuse), PAX8 (strong, diffuse), AE1/AE3, GATA-3 (moderate, diffuse).
	NEGATIVE: CD10, CK20, vimentin, CA9.		NEGATIVE: CD117, CD10, CK20, vimentin, CA9.

	~~This~~ tumour ~~does not completely fit the diagnosis of renal oncocytoma or eosinophilic chromophobe renal cell carcinoma~~.		It is in keeping with "low-grade oncocytic tumour" (LOT), an evolving entity. Based on limited data, LOT appears to have an indolent behavior.

	~~It is in keeping with "low-grade oncocytic~~ tumour~~" (LOT), an evolving entity. Based on limited data, LOT appears to have an indolent behavior~~.		This tumour does not fit the diagnosis of renal oncocytoma or eosinophilic chromophobe renal cell carcinoma.
	</pre>		</pre>

Michael at 14:18, 21 February 2024

2024-02-21T14:18:31Z

← Older revision		Revision as of 14:18, 21 February 2024
Line 65:		Line 65:
	*CK7 +ve.		*CK7 +ve.
	*[[GATA3]] +ve.		*[[GATA3]] +ve.
			**Very rarely positive in RCCs (1/71 clear cell RCC, 0/53 papillary RCC, 2/33 chromophobe RCC).<ref name=pmid2431520>{{cite journal \|authors=Gonzalez-Roibon N, Faraj SF, Munari E, Bezerra SM, Albadine R, Sharma R, Argani P, Allaf ME, Netto GJ \|title=Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms \|journal=Hum Pathol \|volume=45 \|issue=2 \|pages=244–8 \|date=February 2014 \|pmid=24315206 \|doi=10.1016/j.humpath.2013.08.020 \|url=}}</ref>
			**May be positive in oncocytoma (9/47 cases).<ref name=pmid2431520/>
	*PAX8 +ve.		*PAX8 +ve.
	*CD117 -ve.		*CD117 -ve.